Overall, in order to apply DPP-4 inhibitors for treatment of CAVD, further studies were urgently needed to find the DPP4 inhibitor with higher cardiovascular tissue distribution and anti-calcification ability, and then evaluate it in large-scale RCTs. The gene discussed is DPP4; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.